Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I believe the authors reasoning is flawed but do feel the share price will get into .30's -IMO
Solar has some new technology coming into the market but the overall picture is gloom and doom. SATC pps will continue to decline until a 10Q comes out ahead of market projections. IMO
Waiting to reenter. Should be real cautious here. Foresee a steady decline.
The last article I posted from Seeking Alpha sums up my sentiment exactly and how I have felt about this company from years ago having been a Dendreon investor and like Dendreon I expect to make a signifigent return on my investment (in at 3 sold in 40's).
I came across NWB doing my research on Dendreon because NWB was considered the foremost reason Denreon could fail. Bottom line was NWB undercut the cost of Dendreon's treatment and also had a better delivery of medication. The technology works.
If you do not believe in the technology you should move on. If you are onboard with it then you must realize the undervalution here and risk missing out on a sure investment. Considering NWB has mulriple products in the pipeline we could be in for a extremely profitable ride.
Patience will payoff and we dont know when takeoff will be; just thats its coming....soon
I definetly dont want to chase either. I should be able to get a larger position by Thurs.
I believe that also. I need to hurry up and get more shares soon.
I still want to pickup more shares so I hope its staying down for a little bit longer...............self-serving
Looking at the buys there were several buys worth between $30,000 to just over $50,000
Wow.
Someone likes the company like we do...alright maybe a little more.
I looked around and could not find any developments. I am expecting however clinacal results by the first week of April. Maybe there was a leak.............?
Notice this on step-power.com
"Sol-Hy’s success will be the performance and reliability of its panels. All of our patented and patent pending products and their components have been rigorously tested"
Meaning they have proto-types. So we could be much further along than what we might expect at .0045 pps. All just speculation at this point.
Lets get some news this week!
That will be a good day.
We are in a holding pattern all awaiting continued evolution of business processes for the CTCC/STEP to be succesful. We obviously are not there yet. There are many steps but the important thing is we see progression.
Key events would be a 10Q showing some revenue and testing results of the Hybrid solar panel. Not whats posted on otc.
STEP is in its infancy. Less than 6 months old and not a big company with an IPO. If I sense smoke and mirrors I would will be the out.
OTC markets is just an electronic bulletin board and not offical information.
Why doesnt anyone get this? The same subject pops on many boards over and over. Its only for reference.
Its like me starting a investment web page where investors can get company profile information and then I turn around and charge companies to update there business informatiion on my services.
Eventually it will get done; but I really could care less.
Your facts are scewed and I will not provide you your dd. Do your own. I have done mine.
There are many factors that differentiate this company from the other you are refering to. I choose CTCC that says allot. I do very well and am up allot here already.
I am not a lemming.......
Were seeing on this next leg-up the MM's handling the share sales different. I dont see bid wacking manipulation like there was in Febuary.
1. There has not been any paid advertising here to get people to buy in. Just excited share holders.
2. There were no shorts in the month of Feb that were significant.(12k shares)
3. OTC Pink is only as good as the person maintaining and inputing the information. Its an electronic bulletion board. It should only be used as a guide.
Remember this is a very new company under 6months old that has subsideraries making sales according to a few PR's. Its speculative but appears viable. There is regular progress here in building a company. IMO we will see +.01 on one good news worthy pr.
I realize that. I cannot find the new page. Did you?
Were you able to find there new facebook page?
I was not able to; they posted a couple of weeks ago they were opening a new facebook profile.
Costco was a PR. It took us up 1000%. Take it for it is..
The medipendent covers annual 2012 operating cost and "if" fuel additive adds revenue its just icing.
Under valued here but just speculation at this point. I see +.01 happening again.
Very. Its happening. Should be a good week comming up!
Go CTCC/STEP
Amen sue!! Spoken like a true investor.
Dont fall into that trap. There is no shorting here.
No hype needed only facts.
Not at all.
This past week another starter solar company shot upto .08 on its lame stock promo that only disclosed an "speculative invention"(that company has yet to produce a proto-type) and IMO a scam. The share stucture here is also better.
So I assume we will atleast do similar when news hits.
Well stated sueb. Others should take notes.
Largely undervalued and looking to flip a third 100% gain here. Readers of this bored shouldnt let this opportunity to pick up cheap shares slip away.
Nice article. TY
Looks very strong today. Glad I picked up more down at .0025
Why I like NWBO so much:
Taken from Seeking Aplha article. Sites Dendreons success and how NWBO will have better profit margin. So despite the companies tough financials and share dilution we will come out way ahead.
Overcoming The Challenges Of Cell-Based Cancer Immunotherapy
March 20, 2012
Unlike chemotherapy, which directly attacks cancer cells, immunotherapy stimulates a patient's immune system to attack tumors and ultimately prolong survival. Autologous cellular immunotherapy, such as Dendreon's (DNDN) sipuleucel-T (Provenge), uses patients' own immune cells to defend against cancer as these cells are best known as nature's adjuvants and are very powerful in eliciting an immune response. Every dose of Provenge is personalized and made to order for each individual patient. Despite the logistical and manufacturing challenges of personalized immune cell therapy, Provenge is relatively safe and can elicit a sufficient immune response against tumors to improve survival.
Before Provenge was launched in 2010 to treat advanced prostate cancer; many investors questioned whether an autologous cancer immunotherapy was commercially viable. Dendreon has shown, however, that Provenge can be both scalable and profitable, despite problems the company initially had with reimbursement. Unfortunately, Provenge's logistical requirements will ultimately limit its margins compared to non-autologous cancer therapies.
Provenge Under the Microscope - It's All About COGS
Every Provenge patient must undergo three leukapheresis procedures, where typically 1.5 to 2 times the patient's blood volume is withdrawn and peripheral blood monocytes (PBMCs) are isolated with subsequent reintroduction of the blood afterward. The leukapheresis product is then shipped overnight to one of Dendreon's manufacturing facilities and cultured (for 36-44 hours) with a single prostate cancer specific antigen (PAP) that directs the immune system to specifically target prostate cancer cells.
PAP is fused with an immune cell activator known as granulocyte-macrophage colony-stimulating factor (GM-CSF). Culturing PBMCs with the PAP/GM-CSF recombinant fusion protein results in activated antigen presenting cells (APCs), which play a critical role in triggering T-cell killing of tumors. The manufacturing of Provenge is somewhat inefficient since only about 25% of the final manufacturing product actually consists of APCs (a minimum of 50 million APCs). Once manufacturing is complete, Provenge cannot be stored and must be administered to patients within 18 hours of manufacture. Thus, Provenge is shipped overnight back to patients to be administered via intravenous infusion.
Provenge patients have to repeat this process every two weeks for three cycles. To ensure that Provenge is administered within the allotted 18 hours, Dendreon has had to build several manufacturing sites throughout the U.S. As a result of the logistical limitations mentioned previously, Provenge's margins are lower than conventional biological cancer therapies, such as antibodies, which have margins closer to 85%-90%. According to Dendreon's management, Provenge's margins currently are less than 50% and will increase to 60-70% range when the product reaches close to $500 million in sales.
New Kids on the Block: Faster, Cheaper and Better
Newer autologous cellular immunotherapies that may be more effective, as well as may overcome Provenge's logistical shortcomings, are currently being developed. Both Immunocellular Therapeutics (IMUC.OB) and Northwest Biotherapeutics (NWBO.OB) utilize patients' dendritic cells (DCS), which are more potent APCs, to stimulate tumor killing. IMUC is currently enrolling for its lead DC immunotherapy (ICT-107) in a randomized, multicenter, double-blinded Phase II study in patients with glioblastoma multiforme (GBM), a very aggressive form brain cancer.
Unlike Provenge, ICT-107 uses six tumor associated antigens to target tumor cells as well as cancer stem cells, which are more resistant to radiation and chemotherapy. Results from a Phase I study with ICT-107 were very promising. ICT-107 improved patient survival by almost two years compared with the historical standard of care. The manufacturing data released last week from the current phase II manufacturing shows production of 60 doses (30 product and 30 placebo) from a single manufacturing run. According to the IMUC company presentations, the cost per shot of vaccine would be under $500 per shot of vaccine with per shot. This compares very favorably with the cost of manufacture for Provenge which is approximately $15,000 with a retail cost of about $31,000 per infusion.
Lower Cost, Better Logistics - The Future is Here
Patients treated with either ICT-107 or the Northwest Biotherapeutics product DCVax must also undergo a leukapheresis procedure to harvest PBMCs. DCs generated from PBMCs have been shown to stimulate a stronger immune response than APCs. Thus, not as many cells are actually required for treatment. DC manufacturing has become much more efficient. As much as 90% of the final manufacturing product are DCs. One leukapheresis procedure with ICT-107 manufacturing process can produce as many as 30 doses or more as mentioned earlier.
In addition, ICT-107 and DCVax can be stored in a freezer, so patients only need to undergo one leukapheresis procedure instead of three as with Provenge. This also eliminates the need to ship the final product back to patients within 18 hours and the need to have multiple manufacturing facilities. Furthermore, DCs can be administered via intradermal injection rather than IV infusion, which is much less invasive and time consuming for patients. Without all of the logistical liabilities, margins for ICT-107 and DCVax should be in the range of 85%-90% and comparable to that of oncological monoclonal antibodies, like bevacizumab (Avastin) and trastuzumab (Herceptin) from Roche (RHHBY.PK).
All new therapeutic modalities improve with each new generation. OKT3 (muromonab-CD3), the first therapeutic antibody approved by the FDA, was burdened with a very short half-life and production of human anti-mouse antibodies because it was a murine antibody. It was not until second generation (chimeric and humanized) antibodies almost 10 years later that these problems were eventually addressed. It is just a matter of time when autologous cellular immunotherapies evolve into more commercially optimal products. But as developments ensue, there is more excitement that a portion of the market could be carved out by such technology. In a proceeding article I will discuss the differing approaches taken by these companies to that end.
Well it us to buy at a low price until engines start getting delivered but does not help after you bought a piece of the pie!
Shows a poor job of the company with pr.
I don't believe they do a good job of marketing themselves. Allot of investors on the sideline for this one.
We are up 7% on 9,600 volume...............
Allot of 10K blocks getting sold. Dilution? I imagine......
Interesting read as SATC ventures further into the Chinese markets:
http://www.businessweek.com/articles/2012-03-14/inside-the-chinese-boom-in-corporate-espionage
That would go along with not having received an answer when I possed that question to USH Investor relations.
Exactly. Costco isn't selling there product and yet they have sold over 13,000 units already.
Imagine what happens when Costco does come on-line....hmmm
I don't own shares here anymore but need to double them up a third time again.
TA is GAGGED!!!!!
Dilution could be happening!! OMG!!!
Delinquent financials!! Oh my!!
MDHI is an ATM. Crazy not to buy in this low. Have my order in.
I am not under that impression. You on the other hand are under the assumption of the details within that contract and its status. Stating they owe $2.5 mil. Are you sure about that? Whats your implication here. Manufacturing and sales will cease on June 30th? Really?
Your proving my point:
The company never put out you could buy it from Costco. Why do you suggest it is?
It is a process the company is working on. That is what was put out.
Excellent!
Out of my other 5 stocks in my portfolio UHLN has the most upside. Selling some of those to put the money here.